Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease

Soeda,Seiko; Ohyashiki,Junko  H.; Ohtsuki,Kazushige; Umezu,Tomohiro; Setoguchi,Yasuhiro; Ohyashiki,Kazuma

doi:10.3892/ijmm.2013.1251

Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease

Authors:
- Seiko Soeda
- Junko H. Ohyashiki
- Kazushige Ohtsuki
- Tomohiro Umezu
- Yasuhiro Setoguchi
- Kazuma Ohyashiki
View Affiliations

Affiliations: Division of Respiratory Medicine, Tokyo Medical University, Tokyo, Japan, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan, Department of Molecular Science, Tokyo Medical University, Tokyo, Japan
Published online on: January 21, 2013 https://doi.org/10.3892/ijmm.2013.1251
Pages: 533-539

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by both chronic inflammation in the airway and systemic inflammation; however, the molecular mechanism of COPD has not been fully elucidated. By measuring microRNA (miRNA) expression in the plasma of COPD subjects, we aimed to identify the clinical relevance of plasma miRNA levels in these patients. Blood samples were obtained from COPD patients and age-matched normal controls. We initially produced plasma miRNA expression profiles using TaqMan low-density array screening. For further validation, individual qRT-PCRs were performed in 40 COPD patients and 20 healthy subjects. TaqMan low-density array screening showed that 9 miRNAs (miR-29b, miR-483-5p, miR-152, miR-629, miR-26b, miR-101, miR-106b, miR-532-5p and miR-133b) were significantly downregulated in the plasma from COPD patients when compared with normal smokers. Among these miRNAs, we focused on miR-106b. A reduction in the plasma miR-106b levels was evident in COPD ex-smokers and COPD current smokers compared with levels in smokers. There was a negative correlation between the plasma miR-106b level and the duration of disease since diagnosis in COPD ex-smokers and the duration of smoking in COPD current smokers. These findings support the concept that progressive reduction in the plasma miR-106b level may reflect persistent and systemic changes even after the discontinuation of smoking in COPD patients. miR-106b may therefore play an important role in the pathogenesis of COPD.

View Figures

View References

1	Agusti A and Soriano JB: COPD as a systemic disease. COPD. 5:133–138. 2008. View Article : Google Scholar
2	Fabbri LM, Luppi F, Beghe B and Rabe KF: Complex chronic comorbidities of COPD. Eur Respir J. 31:204–212. 2008. View Article : Google Scholar : PubMed/NCBI
3	Celli BR, Cote CG, Marin JM, et al: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 350:1005–1012. 2004. View Article : Google Scholar : PubMed/NCBI
4	Barnes PJ and Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J. 33:1165–1185. 2009. View Article : Google Scholar : PubMed/NCBI
5	Sinden NJ and Stockley RA: Systemic inflammation and comorbidity in COPD: a result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence. Thorax. 65:930–936. 2010.
6	Decramer M, Janssens W and Miravitlles M: Chronic obstructive pulmonary disease. Lancet. 379:1341–1351. 2012. View Article : Google Scholar
7	Chen HY, Yu SL, Li KC and Yang PC: Biomarkers and transcriptome profiling of lung cancer. Respirology. 17:620–626. 2012. View Article : Google Scholar : PubMed/NCBI
8	Katoh Y and Katoh M: Hedgehog signaling, epithelial-tomesenchymal transition and miRNA (Review). Int J Mol Med. 22:271–275. 2008.PubMed/NCBI
9	Lee EM, Shin S, Cha HJ, et al: Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int J Mol Med. 24:45–50. 2009.PubMed/NCBI
10	Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
11	Etheridge A, Lee I, Hood L, Galas D and Wang K: Extracellular microRNA: a new source of biomarkers. Mutat Res. 717:85–90. 2011.PubMed/NCBI
12	Ezzie ME, Crawford M, Cho JH, et al: Gene expression networks in COPD: microRNA and mRNA regulation. Thorax. 67:122–131. 2011. View Article : Google Scholar : PubMed/NCBI
13	Schembri F, Sridhar S, Perdomo C, et al: MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc Natl Acad Sci USA. 106:2319–2324. 2009. View Article : Google Scholar : PubMed/NCBI
14	Hunter MP, Ismail N, Zhang X, et al: Detection of microRNA expression in human peripheral blood microvesicles. PloS One. 3:e36942008. View Article : Google Scholar : PubMed/NCBI
15	Ohyashiki JH, Umezu T, Kobayashi C, et al: Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes. 3:3472010. View Article : Google Scholar : PubMed/NCBI
16	Yoshizawa S, Ohyashiki JH, Ohyashiki M, et al: Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J. 2:e532012. View Article : Google Scholar : PubMed/NCBI
17	Vestbo J and Rennard S: Chronic obstructive pulmonary disease biomarker(s) for disease activity needed urgently. Am J Respir Crit Care Med. 182:863–864. 2010. View Article : Google Scholar : PubMed/NCBI
18	Han MK: Update in chronic obstructive pulmonary disease in 2010. Am J Respir Crit Care Med. 183:1311–1315. 2011. View Article : Google Scholar : PubMed/NCBI
19	Sakao S and Tatsumi K: The importance of epigenetics in the development of chronic obstructive pulmonary disease. Respirology. 16:1056–1063. 2011. View Article : Google Scholar : PubMed/NCBI
20	Pottelberge GR, Mestdagh P, Bracke KR, et al: MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 183:898–906. 2011. View Article : Google Scholar : PubMed/NCBI
21	Sato T, Liu X, Nelson A, et al: Reduced miR-146a increases prostaglandin E in chronic obstructive pulmonary disease fibroblasts. Am J Respir Crit Care Med. 182:1020–1029. 2010. View Article : Google Scholar : PubMed/NCBI
22	Lewis A, Riddoch-Contreras J, Natanek SA, et al: Downregulation of the serum response factor/miR-1 axis in the quadriceps of patients with COPD. Thorax. 67:26–34. 2012. View Article : Google Scholar : PubMed/NCBI
23	Izzotti A, Calin GA, Arrigo P, Steele VE, Croce CM and De Flora S: Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J. 23:806–812. 2012. View Article : Google Scholar : PubMed/NCBI
24	Cushing L, Kuang PP, Qian J, et al: miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol. 45:287–294. 2011. View Article : Google Scholar : PubMed/NCBI
25	Akbas F, Coskunpinar E, Aynaci E, Oltulu YM and Yildiz P: Analysis of serum micro-RNAs as potential biomarker in chronic obstructive pulmonary disease. Exp Lung Res. 38:286–294. 2012. View Article : Google Scholar : PubMed/NCBI
26	Rutgers SR, Postma DS, ten Hacken NH, et al: Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax. 55:12–18. 2000. View Article : Google Scholar : PubMed/NCBI
27	Lapperre TS, Postma DS, Gosman MM, et al: Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax. 61:115–121. 2006. View Article : Google Scholar : PubMed/NCBI
28	Margadant C and Sonnenberg A: Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 11:97–105. 2010. View Article : Google Scholar : PubMed/NCBI
29	Takizawa H, Tanaka M, Takami K, et al: Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med. 163:1476–1483. 2001. View Article : Google Scholar : PubMed/NCBI
30	Mak JC, Chan-Yeung MM, Ho SP, et al: Elevated plasma TGF-beta1 levels in patients with chronic obstructive pulmonary disease. Respir Med. 103:1083–1089. 2009. View Article : Google Scholar : PubMed/NCBI
31	Gong Y, Fan L, Wan H, et al: Lack of association between the TGF-β(1) gene and development of COPD in Asians: a case-control study and meta-analysis. Lung. 189:213–223. 2011.
32	Marwick JA, Kirkham P, Gilmour PS, Donaldson K, Mac NW and Rahman I: Cigarette smoke-induced oxidative stress and TGF-beta1 increase p21waf1/cip1 expression in alveolar epithelial cells. Ann NY Acad Sci. 973:278–283. 2002. View Article : Google Scholar : PubMed/NCBI
33	Ivanovska I, Ball AS, Diaz RL, et al: MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol. 28:2167–2174. 2008. View Article : Google Scholar : PubMed/NCBI